Pharmaceutical Inflation and its Impact on IPMI
A Better Discount, a Bigger Bill: Managing Spending in IPMI
By Johan Porto, Co-Founder and CFO, PharmCare Services.
An international health insurer can negotiate lower medication prices and still see its pharmaceutical bill rise. More members may require treatment, therapies may continue for longer, and prescribing may shift toward more expensive options. For insurers preparing their next renewal cycle, a purchasing success does not necessarily translate into a stable claims budget.
Pharmaceutical inflation therefore deserves a central place in the medical-cost conversation in international private medical insurance. Insurers must protect the economics of coverage while maintaining the access members purchased. TPAs must help deliver that access within agreed authority and budgets. Both need a pharmaceutical strategy that connects treatment decisions, international coordination, and financial accountability.
In a recent iPMI Global article, PharmCare Services CEO Mike Rizo argued that much of an insurer’s pharmaceutical spend sits hidden inside the medical claim. This article takes up the financial question that follows: once that spending is visible, how should a payer budget for it, explain it at renewal, and judge whether it is being managed?
Price, volume, and mix: what is driving the increase
Drug-price inflation means paying more for a comparable medication. Pharmaceutical spending growth also reflects patient numbers, treatment duration, and the mix of therapies. These forces can move in different directions: lower prices in one drug class can coexist with greater expenditure elsewhere. Payers need to distinguish them before deciding how to respond.
New treatment options and expanded indications can increase the population eligible for therapy. Longer treatment duration can add recurring expenditure even without a price increase. A shift toward more costly therapies can raise average cost per patient. These are different budget pressures from an increase in the price of an unchanged prescription, and a single inflation allowance can obscure their effects.
WTW’s 2026 Global Medical Trends Survey projects medical cost growth of 10.3% globally and 11.9% in Latin America. In the Americas, insurers ranked pharmaceutical advances first among the drivers of that growth, ahead of new medical technologies. That ranking reflects insurers’ assessment of cost pressures, not a measured share of medical inflation. [1]
Pharmaceutical Strategies Group provides a complementary view. Its 2026 Artemetrx State of Specialty Spend and Trend Report found that gross specialty spending grew 10.8% in 2025. Claim utilization accounted for approximately 10.6 percentage points of that trend, while cost per claim contributed about 0.1 points. The findings suggest that more members receiving specialty treatment, rather than higher costs per claim, were the principal driver of growth. These are spending-growth figures, not measures of drug-price inflation. [2]
WTW’s international medical trend estimates and PSG’s U.S. specialty claims analysis describe different populations. Neither establishes an IPMI-specific pharmaceutical inflation rate. Their relevance is the question they raise for international payers: how much of your claim’s growth comes from pharmaceuticals, and what is driving it? For a finance team, the second part of that question matters most, because price and volume call for different responses.
Why a better discount can coexist with a bigger bill
Consider a hypothetical portfolio with 100 patients whose treatment costs $50,000 each annually, producing a $5 million bill. If the cost per patient falls by 10% but the treated population rises to 120, expenditure increases to $5.4 million. The payer has lowered the treatment cost and still faces an 8% spending increase.
Procurement alone cannot resolve that budget pressure. Insurers also need to understand treatment patterns, anticipate ongoing commitments, and assess appropriate alternatives with clinical professionals. Increased utilization may represent better access to necessary care. A growing pharmaceutical budget is not, by itself, evidence of poor management.
What annual claims can conceal
For an IPMI underwriter, timing matters. A recurring therapy started late in the policy year may contribute only a few months of claims to the experience used at renewal. If treatment and coverage continue, the next year may contain a full year of expenditure. The expected annual commitment matters more than simply applying a percentage increase to last year’s paid claims.
Portfolio concentration matters too. In a smaller insured population, a few expensive ongoing treatments can materially change claims performance. Payers should examine spending per member alongside the number of treated patients, cost per treatment, and expected duration. Where premium income and claims are denominated in different currencies, exchange-rate movements add another source of pressure that should be identified separately from local drug-price changes.
Raising premiums can help fund higher expected claims, but it does not address avoidable expenditure. It also creates a commercial question at renewal: can the insurer explain what is driving the increase and demonstrate what it has done to manage it? Clear pharmaceutical reporting supports a more credible conversation with brokers, employers, and members.
The international exposure behind the claim
IPMI adds a further complication: members may have coverage across borders, subject to policy terms, while medication availability, provider pricing, and supply arrangements remain country specific.
A member may begin a specialty therapy abroad and continue it after returning home. The clinical need persists, but prescribing requirements, benefit authorization, dispensing, and delivery may change. The payer needs a dependable treatment pathway and a clear view of its total cost. Any alternative must be clinically suitable, permitted locally, and consistent with coverage.
Financial visibility must follow the same pathway. Medication expenditure often sits inside hospital and outpatient charges rather than pharmacy claims. For budgeting, the consequence is easy to miss: moving a therapy from one benefit or treatment setting to another can look like a saving in one budget line while the total cost stays flat or rises. Administration charges and provider margins vary by setting, so payers need the combined cost of a clinically appropriate pathway, not only the cost visible in one claim type.
Even when medication is billed directly through a pharmacy, visibility can remain limited if reports do not provide usable details or contracts leave the pricing basis and intermediary remuneration unclear.
For TPAs, pharmaceutical management should strengthen the service they provide to insurer clients. A specialist partner can support medication coordination and reporting within existing authorization arrangements. Coverage decisions, escalation thresholds, data access, and responsibility for patient follow-up should be explicit. The insurer needs a coherent account of the result, even when several organizations help deliver it.
Accountability beyond the quoted savings
Payers should distinguish a reduction in today’s cost base from a lasting change in the growth rate. A sourcing improvement can produce an immediate saving while new patients or therapies drive spending upward again. That makes pharmaceutical management an ongoing responsibility, with results measured over time.
For a finance team, a quoted discount is only part of the picture: sound budgeting requires a clear understanding of what is being paid, what drives changes in spending, and who is responsible for addressing avoidable costs. Contracts should support that understanding by clearly defining pricing benchmarks, fees, reporting requirements, and audit rights, allowing the payer to verify the total cost and assess whether the reported savings are supported by the underlying costs.
Where to start
A practical starting point is a focused review of pharmaceutical expenditure across medical and pharmacy claims. Identify the major therapies and countries, reconcile the available data, and distinguish changes in patient numbers from changes in treatment cost. Where information is incomplete, define what is missing and how it will be obtained.
The next step is to assign responsibility. Clinical decisions remain with the appropriate treating professionals. Coverage decisions and authorization limits must be clear. The parties should agree who coordinates supply, monitors delivery, resolves exceptions, and reports the result. Those arrangements make the service accountable beyond the initial prescription.
Pharmaceutical inflation cannot be managed through renewal pricing alone. Before the next budgeting cycle, insurers should be able to explain their medication expenditure, anticipate ongoing treatment commitments, and identify who is accountable for acting on the findings.
The role of international pharmaceutical management
At PharmCare Services, we approach this as an international pharmaceutical management responsibility. PCS connects medication access through licensed providers with patient coordination and financial visibility. For insurers and TPAs, the objective is to manage the course of treatment, including subsequent refills and changes in the member’s location, while retaining clear control over coverage and authorization.
For PCS, the value of international pharmaceutical management is in connecting a payer’s information with practical execution. An analysis should lead to an actionable treatment-access plan; coordination should produce a documented result. That is the standard against which insurers and TPAs should assess the service.
IPMI already covers pharmaceutical risk across borders. Managing that risk with the same international reach is essential to sustaining the coverage members rely on.
RELATED READING: The Hidden Line Item: Why Specialty Medications Are the Real Cost Driver Inside Your Medical Claims
References
- WTW. 2026 Global Medical Trends Survey. November 10, 2025. Figures are projections for 2026, not realized results. The study combines insurer and broker inputs across 91 countries; selected countries with volatile inflation are excluded from published global and regional aggregates. This is not a dedicated IPMI study.
https://www.wtwco.com/en-us/insights/2025/10/2026-global-medical-trends-survey
- Pharmaceutical Strategies Group. PSG Report Finds Specialty Drug Utilization is Dominant Driver of Trend, Biosimilar Adoption Reshaping the Market. July 23, 2026. Summary of the 2026 Artemetrx State of Specialty Spend and Trend Report, using 2025 claims data. The report was sponsored by CenterWell Pharmacy.
The portfolio example is illustrative. Recommendations and the application to IPMI are the author’s analysis. The cited studies do not evaluate or endorse PCS.